Targeted Activation of Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist to a Monoclonal Antibody Maintains Antigen Binding and Specificity

Bioconjugate Chemistry

Volumn 26, Issue 8, 2015, Pages 1743-1752

  Gadd, Adam J R ^a   Greco, Francesca ^a   Cobb, Alexander J A ^a   Edwards, Alexander D ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; CHEMICAL ACTIVATION; DRUG PRODUCTS; MASS SPECTROMETRY; SURFACE PLASMON RESONANCE; ULTRAVIOLET SPECTROSCOPY; URANIUM COMPOUNDS;

ANTI-TUMORS; ANTIGEN BINDING; CANCER IMMUNOTHERAPY; CELL-BE; CELL/B.E; CELL/BE; DENDRITICS; NON-SPECIFIC BINDING; TOLL-LIKE RECEPTORS; VACCINE ADJUVANTS;

MONOCLONAL ANTIBODIES;

CD20 ANTIGEN; CONJUGATED RITUXIMAB UC 1V150; RITUXIMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT; TLR7 PROTEIN, HUMAN;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CONJUGATION; DRUG CONJUGATION; HUMAN; HUMAN CELL; LEUKOCYTE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PROTEIN EXPRESSION; SUBSTITUTION REACTION; ULTRAVIOLET SPECTROSCOPY; AGONISTS; ANIMAL; ANTIBODY SPECIFICITY; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; MACROPHAGE; METABOLISM; MONONUCLEAR CELL; MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY SPECIFICITY; CELLS, CULTURED; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; RITUXIMAB; TOLL-LIKE RECEPTOR 7;

EID: 84939641851     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00302     Document Type: Article

References (53)

1. Fukata, M., Vamadevan, A. S., and Abreu, M. T. (2009) Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders Semin. Immunol. 21, 242-253 10.1016/j.smim.2009.06.005
2. Maisonneuve, C., Bertholet, S., Philpott, D. J., and De Gregorio, E. (2014) Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants Proc. Natl. Acad. Sci. U. S. A. 111, 12294-12299 10.1073/pnas.1400478111
3. Botos, I., Segal, D. M., and Davies, D. R. (2011) The structural biology of Toll-like receptors Structure 19, 447-459 10.1016/j.str.2011.02.004
4. Means, T. K., Golenbock, D. T., and Fenton, M. J. (2000) Structure and function of Toll-like receptor proteins Life Sci. 68, 241-258 10.1016/S0024-3205(00)00939-5
5. Kasturi, S. P., Skountzou, I., Albrecht, R. a, Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., and Kwissa, M. et al. 2011, Programming the magnitude and persistence of antibody responses with innate immunity Nature 470, 543-547 10.1038/nature09737
6. Hotz, C. and Bourquin, C. (2012) Timing is everything Oncoimmunology 1, 227-228 10.4161/onci.1.2.18169
7. Lane, T. (2001) BCG immunotherapy for superficial bladder cancer J. R. Soc. Med. 94, 316
8. Dudek, A. Z., Yunis, C., Harrison, L. I., Kumar, S., Hawkinson, R., Cooley, S., Vasilakos, J. P., Gorski, K. S., and Miller, J. S. (2007) First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer Clin. Cancer Res. 13, 7119-7125 10.1158/1078-0432.CCR-07-1443
9. Descamps, D., Hardt, K., Spiessens, B., Izurieta, P., Verstraeten, T., Breuer, T., and Dubin, G. (2009) Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials Hum. Vaccines 5, 332-340 10.4161/hv.5.5.7211
10. Verstraeten, T., Descamps, D., David, M. P., Zahaf, T., Hardt, K., Izurieta, P., Dubin, G., and Breuer, T. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines Vaccine 26, 6630-6638 10.1016/j.vaccine.2008.09.049
11. Garçon, N., Segal, L., Tavares, F., and Van Mechelen, M. (2011) The safety evaluation of adjuvants during vaccine development: The AS04 experience Vaccine 29, 4453-4459 10.1016/j.vaccine.2011.04.046
12. Didierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., and Schiavetti, F. et al. 2009, AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity J. Immunol. 183, 6186-6197 10.4049/jimmunol.0901474
13. Eisenbarth, S. C., Colegio, O. R., OConnor, W., Sutterwala, F. S., and Flavell, R. a. (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants Nature 453, 1122-1126 10.1038/nature06939
14. Li, H., Nookala, S., and Re, F. (2007) Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release J. Immunol. 178, 5271-5276 10.4049/jimmunol.178.8.5271
15. Lambrecht, B. N., Kool, M., Willart, M. a., and Hammad, H. (2009) Mechanism of action of clinically approved adjuvants Curr. Opin. Immunol. 21, 23-29 10.1016/j.coi.2009.01.004
16. Casella, C. R. and Mitchell, T. C. (2008) putting endotoxin to work for us: MPLA as clinical adjuvant Cell. Mol. Life Sci. 65, 3231-3240 10.1007/s00018-008-8228-6
17. Vidal, D. (2006) Topical imiquimod: mechanism of action and clinical applications Mini-Rev. Med. Chem. 6, 499-503 10.2174/138955706776876131
18. Othoro, C., Johnston, D., Lee, R., Soverow, J., Bystryn, J. C., and Nardin, E. (2009) Enhanced immunogenicity of plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic toll-like receptor 7 agonist, imiquimod Infect. Immun. 77, 739-748 10.1128/IAI.00974-08
19. Shackleton, M., Davis, I. D., Hopkins, W., Jackson, H., Dimopoulos, N., Tai, T., Chen, Q., Parente, P., Jefford, M., and Masterman, K.-A et al. 2004, The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand Cancer Immun. 4, 9
20. Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., Holman, R. M., Shapiro, R. L., Berman, R. S., Berner, N., Shao, Y., Manches, O., Pan, L., Venhaus, R. R., Hoffman, E. W., Jungbluth, A., Gnjatic, S., Old, L., Pavlick, A. C., and Bhardwaj, N. et al. 2008, Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant J. Immunol. 181, 776-784 10.4049/jimmunol.181.1.776
21. Feyerabend, S., Stevanovic, S., Gouttefangeas, C., Wernet, D., Hennenlotter, J., Bedke, J., Dietz, K., Pascolo, S., Kuczyk, M., and Rammensee, H.-G et al. 2009, Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer Prostate 69, 917-27 10.1002/pros.20941
22. Cristofaro, P. and Opal, S. M. (2003) The Toll-like receptors and their role in septic shock Expert Opin. Ther. Targets 7, 603-12 10.1517/14728222.7.5.603
23. Kneufermann, P., Nemoto, S., Baumgarten, G., Misra, A., Sivasubramanian, N., Carabello, B. A., and Vallejo, J. G. (2002) Cardiac Inflammation and Innate Immunity in Septic Shock: Is There a Role for Toll-Like Receptors? Chest 121, 1329-1336 10.1152/ajpheart.00763.2001
24. Kurimoto, A., Hashimoto, K., Nakamura, T., Norimura, K., Ogita, H., Takaku, H., Bonnert, R., McInally, T., Wada, H., and Isobe, Y. (2010) Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept J. Med. Chem. 53, 2964-2972 10.1021/jm100070n
25. Xiang, A. X., Webber, S. E., Kerr, B. M., Rueden, E. J., Lennox, J. R., Haley, G. J., Wang, T., Ng, J. S., Herbert, M. R., and Clark, D. L. et al. 2007, Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine Nucleosides, Nucleotides Nucleic Acids 26, 635-640 10.1080/15257770701490472
26. Kurimoto, A., Tobe, M., Ogita, H., Ogino, T., Takaku, H., Ichii, S., Kawakami, H., and Isobe, Y. (2004) Prodrugs of 9-benzyl-8-hydroxy-2-(2-hydroxyethylthio)adenine: potent interferon inducing agents in monkeys Chem. Pharm. Bull. 52, 466-469 10.1248/cpb.52.466
27. Lee, H. J., You, Z., Ko, D. H., and McLean, H. M. (1998) Recent advances in prodrugs and antedrugs Curr. Opin. Drug Discovery Dev. 1, 235-44
28. Wu, C. C. N., Hayashi, T., Takabayashi, K., Sabet, M., Smee, D. F., Guiney, D. D., Cottam, H. B., and Carson, D. a. (2007) Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand Proc. Natl. Acad. Sci. U. S. A. 104, 3990-3995 10.1073/pnas.0611624104
29. Oh, J. Z. and Kedl, R. M. (2010) The Capacity To Induce Cross-Presentation Dictates the Success of a TLR7 Agonist-Conjugate Vaccine for Eliciting Cellular Immunity J. Immunol. 185, 4602-4608 10.4049/jimmunol.1001892
30. Whiteside, T. L. (2008) The tumor microenvironment and its role in promoting tumor growth Oncogene 27, 5904-5912 10.1038/onc.2008.271
31. Gollnick, H., Barona, C. G., Frank, R. G. J., Ruzicka, T., Megahed, M., Maus, J., and Munzel, U. (2008) Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: Conclusion of a 5-year long-term follow-up study in Europe Eur. J. Dermatol. 18, 677-682
32. Stephanou, A. and Latchman, D. S. (2005) Opposing actions of STAT-1 and STAT-3 Growth Factors 23, 177-82 10.1080/08977190500178745
33. Vidal, D., Matías-Guiu, X., and Alomar, A. (2004) Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis Br. J. Dermatol. 151, 656-62 10.1111/j.1365-2133.2004.06094.x
34. Berman, B., Sullivan, T., De Araujo, T., and Nadji, M. (2003) Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle Br. J. Dermatol. 149 (Suppl) 59-61 10.1046/j.0366-077X.2003.05634.x
35. Smith, E. B., Schwartz, M., Kawamoto, H., You, X., Hwang, D., Liu, H., and Scherr, D. S. (2007) Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder J. Urol. 177, 2347-51 10.1016/j.juro.2007.01.112
36. Alley, S. C., Okeley, N. M., and Senter, P. D. (2010) Antibody-drug conjugates: targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14, 529-37 10.1016/j.cbpa.2010.06.170
37. Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., and Borzilleri, R. M. (2014) Antibody-drug conjugates: current status and future directions Drug Discovery Today 19, 869-81 10.1016/j.drudis.2013.11.004
38. Scott, A. M., Wolchok, J. D., and Old, L. J. (2012) Antibody therapy of cancer Nat. Rev. Cancer 12, 278-287 10.1038/nrc3236
39. Pallasch, C. P., Leskov, I., Braun, C. J., Vorholt, D., Drake, A., Soto-Feliciano, Y. M., Bent, E. H., Schwamb, J., Iliopoulou, and Kutsch, B. et al. 2014, Sensitizing protective tumor microenvironments to antibody-mediated therapy Cell 156, 590-602 10.1016/j.cell.2013.12.041
40. Friedberg, J. W., Kelly, J. L., Neuberg, D., Peterson, D. R., Kutok, J. L., Salloum, R., Brenn, T., Fisher, D. C., Ronan, E., and Dalton, V. et al. 2009, Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma Br. J. Haematol. 146, 282-91 10.1111/j.1365-2141.2009.07773.x
41. Ahonen, C. L., Doxsee, C. L., McGurran, S. M., Riter, T. R., Wade, W. F., Barth, R. J., Vasilakos, J. P., Noelle, R. J., and Kedl, R. M. (2004) Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN J. Exp. Med. 199, 775-784 10.1084/jem.20031591
42. Carroll, M. C. (2004) The complement system in regulation of adaptive immunity Nat. Immunol. 5, 981-986 10.1038/ni1113
43. Kreutz, M., Giquel, B., Hu, Q., Abuknesha, R., Uematsu, S., Akira, S., Nestle, F. O., and Diebold, S. S. (2012) Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity PLoS One 7, e40208 10.1371/journal.pone.0040208
44. Heit, A., Maurer, T., Hochrein, H., Bauer, S., Huster, K. M., Busch, D. H., and Wagner, H. (2003) Cutting Edge: Toll-Like Receptor 9 Expression Is Not Required for CpG DNA-Aided Cross-Presentation of DNA-Conjugated Antigens but Essential for Cross-Priming of CD8 T Cells J. Immunol. 170, 2802-2805 10.4049/jimmunol.170.6.2802
45. Platt, N. and Gordon, S. (1998) Scavenger receptors: diverse activities and promiscuous binding of polyanionic ligands Chem. Biol. 5, R193-R203 10.1016/S1074-5521(98)90156-9
46. Schön, M. P. and Schön, M. (2008) TLR7 and TLR8 as targets in cancer therapy Oncogene 27, 190-9 10.1038/sj.onc.1210913
47. Ingham, K. C. and Brew, S. A. (1981) Fluorescent labeling of the carbohydrate moieties of human chorionic gonadotropin and alpha 1-acid glycoprotein Biochim. Biophys. Acta, Protein Struct. 670, 181-9 10.1016/0005-2795(81)90007-6
48. O'Shannessy, D. J., Dobersen, M. J., and Quarles, R. H. (1984) A novel procedure for labeling immunoglobulins by conjugation to oligosaccharide moieties Immunol. Lett. 8, 273-277 10.1016/0165-2478(84)90008-7
49. Vecchi, S., Bufali, S., Uno, T., Wu, T., Arcidiacono, L., Filippini, S., Rigat, F., and OHagan, D. (2014) Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model Eur. J. Pharm. Biopharm. 87, 310-7 10.1016/j.ejpb.2014.01.002
50. Wille-Reece, U., Flynn, B. J., Loré, K., Koup, R. a, Kedl, R. M., Mattapallil, J. J., Weiss, W. R., Roederer, M., and Seder, R. a. (2005) HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates Proc. Natl. Acad. Sci. U. S. A. 102, 15190-15194 10.1073/pnas.0507484102
51. Weterings, J. J., Khan, S., van der Heden, G. J., Drijfhout, J. W., Melief, C. J. M., Overkleeft, H. S., van der Burg, S. H., Ossendorp, F., van der Marel, G. a., and Filippov, D. V. (2006) Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: Towards synthetic epitope-based vaccines Bioorg. Med. Chem. Lett. 16, 3258-3261 10.1016/j.bmcl.2006.03.034
52. Feng, Y., Forsell, M. N. E., Flynn, B., Adams, W., Loré, K., Seder, R., Wyatt, R. T., and Karlsson Hedestam, G. B. (2013) Chemical cross-linking of HIV-1 Env for direct TLR7/8 ligand conjugation compromises recognition of conserved antigenic determinants Virology 446, 56-65 10.1016/j.virol.2013.07.028
53. Casi, G. and Neri, D. (2012) Antibody-drug conjugates: basic concepts, examples and future perspectives J. Controlled Release 161, 422-8 10.1016/j.jconrel.2012.01.026